WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced the appointment of Katina Dorton to its Board of Directors, effective immediately. Dorton brings more than 30 years of experience in finance, investment banking, and executive leadership across the healthcare and life sciences sectors.
“Katina brings to Prelude an abundance of experience as a strategic and financial advisor to our leadership team,” said Kris Vaddi, Ph.D., Chief Executive Officer of Prelude Therapeutics. “We welcome her to our board and we look forward to her immediate contributions as we aim to advance our precision oncology drug candidates.”
Dorton most recently served as Chief Financial Officer at NodThera and previously held senior financial roles at Repare Therapeutics, AVROBIO, and Immatics. At Repare Therapeutics, she helped prepare the company for an initial public offering and raised more than $82 million in crossover funding. Earlier in her career, she spent 15 years in investment banking with Morgan Stanley and Needham & Company.
She currently serves on the boards of Mallinckrodt Pharmaceuticals plc, Fulcrum Therapeutics, TScan Therapeutics, and Sonoma Biotherapeutics. Dorton earned her B.A. from Duke University, an M.B.A. from George Washington University, and a J.D. from the University of Virginia School of Law.
“Prelude has an exciting pipeline of novel precision oncology drug candidates, a strong, experienced leadership team, and the opportunity to create significant shareholder value,” said Dorton. “I am excited for the opportunity to work closely with this team along with my fellow board members to help guide the company towards meeting its strategic goals.”
Dorton will succeed Mardi C. Dier, who will resign from the Prelude board effective October 17, 2025, and will also assume Dier’s role as Audit Committee Chair at that time. Dier has served on the board since August 2020.
“I want to take this moment to thank Mardi for her devoted service and invaluable contributions during her time on Prelude’s board,” said Vaddi. “She has been an important resource to me professionally and others on our executive leadership team since becoming a public company in 2020. On behalf of the entire company, we wish Mardi continued success in her endeavors.”
Prelude Therapeutics, a clinical-stage precision oncology company, continues to advance its pipeline of novel therapeutics aimed at improving outcomes for patients with difficult-to-treat cancers.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.